Medicare beneficiaries who rely on Ozempic or Wegovy will pay no more than $274 for a 30-day supply starting January 1, 2027, after the Centers for Medicare and Medicaid Services locked in a negotiated price through the second cycle of the Medicare Drug Price Negotiation Program. The drugs, manufactured by Novo Nordisk, were among 15 selected medications that together accounted for roughly $42.5 billion in Part D gross covered prescription drug costs in 2024 and served 5.3 million Medicare users. The price cut arrives just as a separate GLP-1 Bridge demonstration is set to run through the end of 2027, creating overlapping federal programs that will reshape how seniors access some of the most expensive medications on the market.
Why a $274 monthly GLP-1 price changes the math for millions
Before this negotiation, Ozempic and Wegovy carried list prices that placed them among the costliest drugs in Part D. Reducing the 30-day supply to $274 directly lowers what Medicare plans pay and, by extension, what beneficiaries owe in cost-sharing. The 15 drugs selected for this second negotiation cycle reached millions of enrollees in 2024, a population large enough that even modest per-unit savings compound into billions in reduced federal spending.
For individual patients, the impact will vary by plan design but will be most visible for those who have already hit the initial coverage phase or catastrophic threshold. Because the negotiated $274 figure represents a maximum fair price for a 30-day supply, Part D sponsors can use it as a ceiling while still competing on premiums and cost-sharing. Beneficiaries who previously rationed doses or skipped refills due to cost could see a more predictable monthly bill, particularly if plans move GLP-1 drugs to preferred specialty tiers.
The change also alters incentives for prescribers and health systems. Clinicians treating diabetes or obesity in older adults have faced a trade-off between clinical benefit and financial burden. A capped Medicare price reduces the risk that a new GLP-1 prescription will push a patient into high out-of-pocket spending for the year. Over time, that could expand the pool of eligible patients who are actually started on semaglutide, especially in primary care practices serving low-income seniors.
A separate question is whether the lower Medicare price will pull commercially insured patients toward Part D coverage. Many working-age adults currently pay steep out-of-pocket costs for GLP-1 drugs through employer plans. If the $274 negotiated rate makes Medicare Part D meaningfully cheaper than commercial alternatives, some dual-eligible or newly aging-in beneficiaries could accelerate their enrollment. CMS enrollment and spending dashboards would be the first place to detect such a shift, likely visible by late 2027 as the negotiated price and the GLP-1 Bridge demonstration overlap.
CMS timeline and Novo Nordisk’s role in the second negotiation cycle
The path to this price followed a structured federal timeline. CMS released draft guidance in May 2024 and finalized it in October 2024, laying out the criteria for selecting high-spend drugs and the data manufacturers must submit. The agency then identified Ozempic, Rybelsus, and Wegovy as part of the second set of products subject to negotiation, confirming Novo Nordisk as the manufacturer for all three semaglutide drugs. CMS subsequently announced that Novo Nordisk would participate in the negotiation process, as detailed in its manufacturer participation fact sheet.
Negotiations are taking place during 2025, with the resulting maximum fair prices scheduled to take effect on January 1, 2027. Under the statute, CMS evaluates clinical benefit, unmet medical need, and comparative effectiveness, along with manufacturer research and development costs, federal support, and sales data. Novo Nordisk, in turn, can submit evidence and counterproposals, but ultimately must accept the CMS-determined maximum fair price or face excise taxes and potential exclusion from Medicare and Medicaid.
To support implementation, CMS has published detailed negotiated price files that include a 30-day equivalent supply price, an NDC-9 per-unit price, and an NDC-11 package price for each selected drug, along with written explanations of how each maximum fair price was derived. These documents give Part D plan sponsors the data they need to update formularies, renegotiate contracts with pharmacy benefit managers, and set beneficiary cost-sharing tiers ahead of the 2027 plan year.
How the GLP-1 Bridge demonstration interacts with negotiated prices
Running in parallel, the GLP-1 Bridge demonstration covers July 1, 2026 through December 31, 2027. That program explicitly references Ozempic, Rybelsus, and Wegovy and is designed to test expanded access to GLP-1 medications for certain Medicare populations, including beneficiaries whose coverage has historically been limited for weight-related indications. Because the demonstration begins six months before negotiated prices take effect, it will initially operate under pre-negotiation pricing and then transition to the $274 cap for a 30-day supply in 2027.
The overlap raises practical questions for plans and providers. Part D sponsors participating in the demonstration will need to coordinate benefit design so that beneficiaries moving between standard coverage and the GLP-1 Bridge do not face abrupt changes in out-of-pocket costs. Once the negotiated maximum fair price is in place, both the demonstration and regular Part D benefit will draw on the same underlying price benchmark, simplifying some aspects of administration but potentially increasing volume as affordability improves.
For policymakers, the combined effect of the negotiation program and the GLP-1 Bridge will offer an early test of whether lower prices and targeted demonstrations can expand access without destabilizing plan finances. If utilization rises sharply but total spending per patient falls, CMS could view the $274 semaglutide price as a model for future negotiation cycles. Conversely, if plans report unexpected cost pressures even at the negotiated rate, it may influence how aggressively CMS pursues price reductions for other high-cost drugs in subsequent rounds.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
